Press & event

Vad händer?

Håll dig uppdaterad om våra senaste nyheter och event.

Displaying 1 - 10 of 111

Insights

Of course, in a shifting regulatory environment with evolving customer demands, CDMOs must always be thinking about what is next.

Insights

Pharmaceutical firms are increasingly interested in developing inhaled and nasal delivery formulations. Among many other benefits, administrating drugs via inhalation can reduce the likelihood of patients experiencing adverse effects.

Insights

By acquiring new facilities, CDMOs can add new and complementary capabilities, increase capacity, and expand geographical reach.

Insights

There is no substitution for experience when it comes to taking substances from pre-clinical to clinical and then to commercial scale. 

Insights

With popularity of online pharmacies rapidly increasing and the pharmaceutical black-market has spread into mainstream society and become a widespread issue.

Insights

The Spanish pharmaceutical market has proven to be a key source of growth for Recipharm, since the acquisition of its facilities in both Parets and Leganes.

Insights

A drug substance project’s movement from pre-clinical to clinical and then into commercial scale manufacture often presents challenges which can lead to failure.

Insights

Many companies underestimated the complexity of implementing serialisation solutions.

Insights

Outsourcing offers pharmaceutical companies many benefits. For example, contract development and manufacturing organisations (CDMOs) possess specialised expertise, knowledge and capabilities in the areas required for the development and manufacture of drug products.

Insights

Inhaled products represent one of the most effective strategies to deliver therapeutic concentrations directly to the site of treatment.